title: Does adjuvant vaccine therapy really have activity in malignant melanoma?
authors.forename: Keith
authors.initials: K
authors.lastname: Wheatley
authors.forename: Natalie J
authors.initials: NJ
authors.lastname: Ives
authors.forename: Paul
authors.initials: P
authors.lastname: Lorigan
mesh_terms: D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D006801:Humans; D016233:Immunotherapy, Active; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008545:Melanoma / Q000556:secondary / Q000628:therapy*; D009364:Neoplasm Recurrence, Local; D011994:Recombinant Proteins; D012107:Research Design; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D019496:Cancer Vaccines; D004338:Drug Combinations; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins